市場調査レポート
商品コード
1280763

米国の静注用免疫グロブリン市場の2028年までの予測 - タイプ別、用途別、流通チャネル別、エンドユーザー別の国別分析

US Intravenous Immunoglobulin Market Forecast to 2028 - Country Analysis By Type, Application, Distribution Channel, and End User

出版日: | 発行: The Insight Partners | ページ情報: 英文 145 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.25円
米国の静注用免疫グロブリン市場の2028年までの予測 - タイプ別、用途別、流通チャネル別、エンドユーザー別の国別分析
出版日: 2023年04月19日
発行: The Insight Partners
ページ情報: 英文 145 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の静注用免疫グロブリン市場規模は、2022年に44億3,926万米ドルとなり、2028年には71億563万米ドルに達すると予測されており、2023年から2028年の間にCAGR 8.2%で成長すると推測されています。老年人口の増加は、米国の静注用免疫グロブリン市場の成長を後押ししています。

免疫グロブリンは、身体の免疫システムによって自然に作られる抗体で、感染症や病気と闘うのに役立ちます。免疫グロブリン欠乏症の患者は、免疫グロブリンの外部投与が必要であり、免疫グロブリン補充療法(IgRT)として知られています。IgRTは、静脈内投与と皮下投与があります。免疫グロブリン静注療法(IVIg)と免疫グロブリン皮下注療法(SCIg)は、適応と重症度によって選択されます。IVIgは、ヒトの血漿から抽出されます。これらの抗体は、免疫疾患、血液疾患、神経疾患など様々な疾患の治療に使用されています。米国では、免疫不全疾患の有病率の上昇や老人人口の増加などの要因が、米国の静注用免疫グロブリン市場の成長を後押ししています。しかし、免疫グロブリン療法による副作用が市場成長の妨げとなっています。

IVIGは、原発性および二次性免疫不全や自己免疫疾患に苦しむ患者の治療に使用されます。IVIGは、ほとんどの原発性免疫不全症(PID)を治療するための標準的な治療法です。ジョン・ホプキンス医学研究所のデータによると、米国の総人口の約3%、すなわち1,000万人が自己免疫疾患に苦しんでいるとされています。米国国立アレルギー感染症研究所(NIAID)によると、200種類以上の原発性免疫不全症(PIDD)が存在し、米国では50万人以上の人が罹患しています。この希少な遺伝性疾患は、慢性的で体力が低下し、治療費が高額になることがあります。免疫性血小板減少症(ITP)は、血小板が異常に少ないことを特徴とする自己免疫性出血性疾患であり、血小板減少症と呼ばれる状況です。米国では、成人におけるITPの発症率は10万人あたり3.3人であるとRare Diseases Organizationは発表しています。2019年に発表された全米多発性硬化症協会の調査報告書によると、米国では~100万人の成人(~913,925人)が多発性硬化症(MS)に罹患していました。MSディスカバリーフォーラムによると、米国では毎週、~200件の新しい症例が診断されています。このように、免疫不全疾患の有病率の増加は、米国の静注用免疫グロブリン市場の成長を牽引しています。

米国の静注用免疫グロブリン市場に参入している多くの市場関係者や研究機関は、製品ポートフォリオを拡大し、市場シェアを拡大するために先進的な技術開発を進めています。免疫不全疾患の有病率の上昇、製品の承認、共同研究などは、米国の静注用免疫グロブリン市場規模を押し上げる要因のひとつです。

米国の静注用免疫グロブリンに関連する最近の動向のいくつかを以下に紹介します:

2020年4月、Kamada Ltd.とKedrion Biopharmaは、COVID-19に対する潜在的治療薬として、ヒト血漿由来の抗SARS-CoV-2(COVID-19)ポリクローナル免疫グロブリン(IgG)製品を開発、製造、販売するために協力しました。今回の発表は、このような製品の開発プログラムの開始について、両社が別々に報告していたものです。

2022年1月、LFBとKedrionは、フランスにおける患者さんへの免疫グロブリンの供給を増やすための産業協力協定を結びました。この産業協力の枠組みで、ケドリオンは、フランスで「Etablissement Francais du Sang」(EFS)により採取されたLFBの血漿からハンガリーで免疫グロブリンを製造しました。LFBは、フランスの保健当局と合意し、その管理下で、ケドリオンがフランスで製造したこの免疫グロブリンを輸入し、フランス中の病院で入手できる免疫グロブリンを補完しています。

2020年4月、オクタファーマはCSL、武田薬品、BPL、Biotest、LFBと共同で、血漿由来超免疫免疫グロブリンによるCOVID-19の治療の可能性を検討しました。

米国の静注用免疫グロブリン市場、タイプ別インサイト

製品タイプに基づき、米国の静注用免疫グロブリン市場は、IgG、IgM、IgA、その他に区分されます。2022年には、IgGセグメントが市場で最大のシェアを占めています。さらに、同セグメントは予測期間中に最も高いCAGRを記録すると予想されています。

IVIgは、抗体欠乏症の患者、または免疫不全症に苦しむ患者のための補充療法および治療法です。例えば、原発性または二次性低ガンマグロブリン血症では、IVIg補充療法により、血液中の十分な量のIgGを投与することで感染症に対する防御を行います。IVIgは、血漿からIgGのみを精製してIVIg製剤を製造するため、1バッチあたり1,000~15,000人のドナーに由来する血清から調製される血液製剤です。そのため、治療薬として使用されるIVIgは、95~98%の純度のIgGを含み、IgAやIgMなどの他の血漿タンパク質が少量含まれています。

このように、IgGが様々な疾患の治療に幅広く応用されていることが、米国の静注用免疫グロブリン市場の成長に寄与している要因の一つです。

米国の静注用免疫グロブリン市場、エンドユーザー別インサイト

米国の静注用免疫グロブリン市場は、エンドユーザーに基づいて、低ガンマグロブリン血症、慢性炎症性脱髄性多発神経炎(CIDP)、免疫不全症、重症筋無力症(MG)、多巣性運動神経障害(MMN)、特発性血小板減少性紫斑病(ITP)、炎症性筋萎縮症、特異抗体欠損症(SDA)、ギランバレー症候群(GBS)などと区分されています。2022年には、免疫不全疾患セグメントが最大の市場シェアを占め、.同分野は今後数年間、最も速い速度で成長することが予想されます。

世界保健機関(WHO)、米国国勢調査局、米国国立医学図書館は、米国の静注用免疫グロブリン市場に関する報告書を作成する際に参照した主要な一次および二次情報の一部です。

目次

第1章 イントロダクション

第2章 静注用免疫グロブリン市場- 主要な要点

第3章 調査手法

  • カバレッジ
  • 2次調査
  • 1次調査

第4章 静注用免疫グロブリン市場- 市場情勢

  • PEST分析
    • 米国-PEST分析
  • 専門家の見解
  • パイプライン製品

第5章 米国の静注用免疫グロブリン市場- 主な市場力学

  • 市場促進要因
    • 免疫不全疾患の有病率の上昇
    • 老年人口の増加
  • 市場抑制要因
    • 免疫グロブリン療法別副作用
  • 市場機会
    • 製薬業界の発展
  • 今後の動向
    • IVIG候補化合物の強力なパイプライン
  • 影響度分析

第6章 静注用免疫グロブリン市場-米国分析

  • 米国の静注用免疫グロブリン市場収益と予測・分析
  • 主要プレイヤーの市場ポジショニング

第7章 米国の静注用免疫グロブリン市場分析- タイプ別

  • 米国の静注用免疫グロブリン市場:タイプ別-2028年までの数量・予測(メトリックトン)
  • IgG
  • IgM
  • IgA
  • その他

第8章 米国の静注用免疫グロブリン市場分析-用途別

  • 低ガンマグロブリン血症
  • 慢性炎症性脱髄性多発ニューロパチー(CIPD)
  • 免疫不全症(Immunodeficiency Diseases
  • 重症筋無力症(Myasthenia Gravis
  • 多巣性運動ニューロパチー
  • 特発性血小板減少性紫斑病(Idiopathic Thrombocytopenic Purpura
  • 炎症性ミオパチー
  • 特異的抗体欠損症
  • ギラン・バレー症候群
  • その他

第9章 米国の静注用免疫グロブリン市場分析 - 流通チャネル別

  • 病院薬局
  • 小売薬局
  • その他

第10章 米国の静注用免疫グロブリン市場分析-エンドユーザー別

  • 病院
  • 専門クリニック
  • その他

第11章 米国の静注用免疫グロブリン市場

  • 米国

第12章 米国の静注用免疫グロブリン市場- 業界情勢

  • 米国静注用免疫グロブリン市場における成長戦略(%)
  • 有機的な展開
  • 無機的な展開

第13章 企業プロファイル

  • Takeda Pharmaceutical Co Ltd
  • Grifols SA
  • Pfizer Inc
  • ADMA Biologics, Inc.
  • Bio Products Laboratory Ltd.
  • Octapharma AG
  • Kedrion SpA
  • CSL Ltd
  • LFB Group
  • Prothya Biosolutions B.V.

第14章 付録

図表

List Of Tables

  • Table 1. Pipeline Product Developments in the US Intravenous Immunoglobulin Market
  • Table 2. R&D Investments by Major Pharmaceuticals Companies in US
  • Table 3. United States Intravenous Immunoglobulin Market, by Type - Volume and Forecast to 2028 (Metric Tons)
  • Table 4. United States Intravenous Immunoglobulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. United States Intravenous Immunoglobulin Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. United States Intravenous Immunoglobulin Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. United States Intravenous Immunoglobulin Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. Organic Developments in the US Intravenous Immunoglobulin Market
  • Table 9. Inorganic Developments in the US Intravenous Immunoglobulin Market
  • Table 10. Glossary of Terms

List Of Figures

  • Figure 1. Intravenous Immunoglobulin Market Segmentation
  • Figure 2. United States Intravenous Immunoglobulin Market Overview
  • Figure 3. IgG Held Largest Share of Intravenous Immunoglobulin Market
  • Figure 4. United States Intravenous Immunoglobulin Market, Industry Landscape
  • Figure 5. US PEST Analysis
  • Figure 6. Expert Opinion
  • Figure 7. US Intravenous Immunoglobulin Market Impact Analysis of Drivers and Restraints
  • Figure 8. United States Intravenous Immunoglobulin Market - Revenue Forecast and Analysis - 2020- 2028
  • Figure 9. Market Positioning of Key Players in United States Intravenous Immunoglobulin Market
  • Figure 10. United States Intravenous Immunoglobulin Market, by Type, 2022 & 2028 (%)
  • Figure 11. IgG: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. IgM: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. IgA: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 15. United States Intravenous Immunoglobulin Market, by Application, 2022 & 2028 (%)
  • Figure 16. Hypogammaglobulinemia: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. CIPD: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 18. Immunodeficiency Disease: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 19. Myasthenia Gravis: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. Inflammatory Myopathies: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 23. Specific Antibody Deficiency: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Guillain-Barre Syndrome: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. United States Intravenous Immunoglobulin Market, by Distribution Channel, 2022 & 2028 (%)
  • Figure 27. Hospital Pharmacy: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 28. Retail Pharmacy: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. United States Intravenous Immunoglobulin Market, by End User, 2022 & 2028 (%)
  • Figure 31. Hospitals: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 32. Specialty Clinics: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. Impact of COVID-19 Pandemic on US Intravenous Immunoglobulin Market
  • Figure 35. Growth Strategies in US Intravenous Immunoglobulin Market (%)
目次
Product Code: TIPRE00029893

The US intravenous immunoglobulin market size was valued at US$ 4,439.26 million in 2022 and is projected to reach US$ 7,105.63 million by 2028; it is estimated to grow at a CAGR 8.2% during 2023-2028. The increasing geriatric population favors the growth of the US intravenous immunoglobulin market.

Immunoglobulins are the antibodies produced naturally by the body's immune system, which help fight infection and disease. Individuals with immunoglobulin deficiency require the external administration of immunoglobulin and known as immunoglobulin replacement therapy (IgRT). IgRT can be given intravenously and subcutaneously. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are selected based on the indication and severity. IVIgs are extracted from human plasma. These antibodies are used in the treatment of various immunological, hematological, and neurological illnesses. Factors such as rising immunodeficiency disease prevalence and increasing geriatric population in the US drive the US intravenous immunoglobulin market growth. However, adverse effects of immunoglobulin therapy hamper the market growth.

IVIGs are used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. The IVIG is a standard therapy to treat most primary immunodeficiencies (PIDs). According to data by John Hopkins Medicine, ~3% of the total US population, i.e., 10 million people, suffers from autoimmune diseases. As per the National Institute of Allergy and Infectious Diseases (NIAID), there are over 200 different types of primary immune deficiency diseases (PIDDs) affecting ~500,000 people in the US. The rare genetic diseases can be chronic, weakening, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. The Rare Diseases Organization states that the incidence rate of ITP in adults is ~3.3 per 100,000 per year in the US. Per the National Multiple Sclerosis Society study report, published in 2019, ~1 million adults (~913,925) were affected by multiple sclerosis (MS) in the US. According to the MS Discovery Forum, ~200 new cases are diagnosed each week in the US. Thus, the increasing prevalence of immunodeficiency diseases drives the growth of the US intravenous immunoglobulin market.

Many market players and research institutes operating in the US intravenous immunoglobulin market are developing advanced technologies to expand their product portfolios and increase their market shares. Rising immunodeficiency disease prevalence, product approvals, and collaborations are among the factors driving the US intravenous immunoglobulin market size.

A few of the recent developments related to US intravenous immunoglobulin are mentioned below:

In April 2020, Kamada Ltd. and Kedrion Biopharma collaborated to develop, manufacture, and distribute a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment against COVID-19. The announcement follows separate previous reports by the two entities concerning initiating development programs for such products.

In January 2022, LFB and Kedrion joined forces in an industrial cooperation agreement to increase the availability of immunoglobulins for patients in France. In the framework of this industrial partnership, Kedrion manufactured immunoglobulins in Hungary from LFB plasma which was collected in France by the "Etablissement Francais du Sang" (EFS). LFB imported these immunoglobulins manufactured by Kedrion in France and complemented its immunoglobulins, which are available in hospitals across France, in agreement with and under the control of French health authorities.

In April 2020, In April 2020, Octapharma collaborated with CSL, Takeda, BPL, Biotest, and LFB to investigate the possibility of treating COVID-19 with plasma-derived hyperimmune immunoglobulins.

US Intravenous Immunoglobulin Market, By Type-Based Insights

Based on product type, the US intravenous immunoglobulin market is segmented into IgG, IgM, IgA, and others. In 2022, the IgG segment held the largest share of the market. Moreover, the same segment is expected to record the highest CAGR during the forecast period.

IVIg is a replacement therapy and treatment for patients with antibody deficiencies or for those who suffer from immunodeficiency disorders. For instance, in primary or secondary hypogammaglobulinemia, IVIg replacement therapy provides protection against infections by administering an adequate volume of IgG in the blood. IVIg is a blood product prepared from serum derived from 1,000-15,000 donors per batch where only IgG is purified from plasma to produce IVIg products. Therefore, IVIg used for treatment therapies contains 95-98% pure IgG with small amounts of other plasma proteins, including IgA and IgM.

Thus, wide applications of IgG in treating several categories of disorders are among the factors contributing to the growth of the US intravenous immunoglobulin market.

US Intravenous Immunoglobulin Market, By End User-Based Insights

The US intravenous immunoglobulin market, based on end user, is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. In 2022, the immunodeficiency diseases segment held the largest market share in . The same segment is expected to grow at the fastest rate during the coming years.

The World Health Organization (WHO), the US Census Bureau, and the US National Library of Medicine are a few of the major primary and secondary sources referred to while preparing the report on the US intravenous immunoglobulin market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the US intravenous immunoglobulin market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the US intravenous immunoglobulin market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Germany market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Intravenous Immunoglobulin Market - By Type
    • 1.3.2 Intravenous Immunoglobulin Market - By Application
    • 1.3.3 Intravenous Immunoglobulin Market - By Distribution Channel
    • 1.3.4 Intravenous Immunoglobulin Market - By End User
    • 1.3.5 Intravenous Immunoglobulin Market - By Country

2. Intravenous Immunoglobulin Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Intravenous Immunoglobulin Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 US - PEST Analysis
  • 4.3 Expert Opinion
  • 4.4 Pipeline Product

5. United States Intravenous Immunoglobulin Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Immunodeficiency Disease Prevalence
    • 5.1.2 Increasing Geriatric Population
  • 5.2 Market Restraints
    • 5.2.1 Adverse Effects of Immunoglobulin Therapy
  • 5.3 Market Opportunities
    • 5.3.1 Flourishing Pharmaceutical Industry
  • 5.4 Future Trends
    • 5.4.1 Strong Pipeline of IVIG Candidates
  • 5.5 Impact Analysis

6. Intravenous Immunoglobulin Market - US Analysis

  • 6.1 United States Intravenous Immunoglobulin Market Revenue Forecast and Analysis
  • 6.2 Market Positioning of Key Players

7. United States Intravenous Immunoglobulin Market Analysis - by Type

  • 7.1 Overview
  • 7.2 United States Intravenous Immunoglobulin Market, by Type - Volume and Forecast to 2028 (Metric Tons)
  • 7.3 United States Intravenous Immunoglobulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 IgG
    • 7.4.1 Overview
    • 7.4.2 IgG: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 IgM
    • 7.5.1 Overview
    • 7.5.2 IgM: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 IgA
    • 7.6.1 Overview
    • 7.6.2 IgA: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)

8. United States Intravenous Immunoglobulin Market Analysis - by Application

  • 8.1 Overview
  • 8.2 United States Intravenous Immunoglobulin Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • 8.3 Hypogammaglobulinemia
    • 8.3.1 Overview
    • 8.3.2 Hypogammaglobulinemia: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Chronic Inflammatory Demyelinating Polyneuropathy (CIPD)
    • 8.4.1 Overview
    • 8.4.2 CIPD: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.5 Immunodeficiency Diseases
    • 8.5.1 Overview
    • 8.5.2 Immunodeficiency Disease: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.6 Myasthenia Gravis
    • 8.6.1 Overview
    • 8.6.2 Myasthenia Gravis: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.7 Multifocal Motor Neuropathy
    • 8.7.1 Overview
    • 8.7.2 Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.8 Idiopathic Thrombocytopenic Purpura
    • 8.8.1 Overview
    • 8.8.2 Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.9 Inflammatory Myopathies
    • 8.9.1 Overview
    • 8.9.2 Inflammatory Myopathies: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.10 Specific Antibody Deficiency
    • 8.10.1 Overview
    • 8.10.2 Specific Antibody Deficiency: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.11 Guillain-Barre Syndrome
    • 8.11.1 Overview
    • 8.11.2 Guillain-Barre Syndrome: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.12 Others
    • 8.12.1 Overview
    • 8.12.2 Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)

9. United States Intravenous Immunoglobulin Market Analysis - by Distribution Channel

  • 9.1 Overview
  • 9.2 United States Intravenous Immunoglobulin Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
  • 9.3 Hospital Pharmacy
    • 9.3.1 Overview
    • 9.3.2 Hospital Pharmacy: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Retail Pharmacy
    • 9.4.1 Overview
    • 9.4.2 Retail Pharmacy: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Others
    • 9.5.1 Overview
    • 9.5.2 Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)

10. United States Intravenous Immunoglobulin Market Analysis - by End User

  • 10.1 Overview
  • 10.2 United States Intravenous Immunoglobulin Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • 10.3 Hospitals
    • 10.3.1 Overview
    • 10.3.2 Hospitals: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.4 Specialty Clinics
    • 10.4.1 Overview
    • 10.4.2 Specialty Clinics: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.5 Others
    • 10.5.1 Overview
    • 10.5.2 Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)

11. United States Intravenous Immunoglobulin Market: Impact Assessment of COVID-19 Pandemic

  • 11.1 US: Impact Assessment of COVID-19 Pandemic

12. US Intravenous Immunoglobulin Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in US Intravenous Immunoglobulin Market (%)
  • 12.3 Organic Developments
    • 12.3.1 Overview
  • 12.4 Inorganic Developments
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Takeda Pharmaceutical Co Ltd
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Grifols SA
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Pfizer Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 ADMA Biologics, Inc.
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Bio Products Laboratory Ltd.
        • 13.5.1.1.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Octapharma AG
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Kedrion SpA
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 CSL Ltd
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 LFB Group
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Prothya Biosolutions B.V.
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms